Recommendations for clinical trial development in mantle cell lymphoma

Stephen Spurgeon, Brian G. Till, Peter Martin, Andre H. Goy, Martin P. Dreyling, Ajay K. Gopal, Michael LeBlanc, John P. Leonard, Jonathan W. Friedberg, Lawrence Baizer, Richard F. Little, Brad S. Kahl, Mitchell R. Smith

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) comprises around 6% of all non-Hodgkin's lymphoma (NHL) diagnoses. In younger patients, age less than 60 to 65 years, aggressive induction often followed by consolidation with autologous stem cell transplant has suggested improved outcomes in this population. Less intensive therapies in older patients often followed by maintenance have been studied or are under active investigation. However, despite recent advances, MCL remains incurable, with a median overall survival of around five years. Patients with high-risk disease have particularly poor outcomes. Treatment varies widely across institutions, and to date no randomized trials comparing intensive vs less intensive approaches have been reported. Although recent data have highlighted the heterogeneity of MCL outcomes, patient assessment for treatment selection has largely been driven by patient age with little regard to fitness, disease biology, or disease risk. One critical advance is the finding that minimal residual disease status (MRD) after induction correlates with long-term outcomes. As such, its use as a potential end point could inform clinical trial design. In order to more rapidly improve the outcomes of MCL patients, clinical trials are needed that prospectively stratify patients on the basis of MCL biology and disease risk, incorporate novel agents, and use MRD to guide the need for additional therapy.

Original languageEnglish (US)
Article numberdjw263
JournalJournal of the National Cancer Institute
Volume109
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Mantle-Cell Lymphoma
Clinical Trials
Residual Neoplasm
Patient Outcome Assessment
Therapeutics
Non-Hodgkin's Lymphoma
Cell Biology
Stem Cells
Maintenance
Transplants
Survival
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Spurgeon, S., Till, B. G., Martin, P., Goy, A. H., Dreyling, M. P., Gopal, A. K., ... Smith, M. R. (2017). Recommendations for clinical trial development in mantle cell lymphoma. Journal of the National Cancer Institute, 109(1), [djw263]. https://doi.org/10.1093/jnci/djw263

Recommendations for clinical trial development in mantle cell lymphoma. / Spurgeon, Stephen; Till, Brian G.; Martin, Peter; Goy, Andre H.; Dreyling, Martin P.; Gopal, Ajay K.; LeBlanc, Michael; Leonard, John P.; Friedberg, Jonathan W.; Baizer, Lawrence; Little, Richard F.; Kahl, Brad S.; Smith, Mitchell R.

In: Journal of the National Cancer Institute, Vol. 109, No. 1, djw263, 2017.

Research output: Contribution to journalReview article

Spurgeon, S, Till, BG, Martin, P, Goy, AH, Dreyling, MP, Gopal, AK, LeBlanc, M, Leonard, JP, Friedberg, JW, Baizer, L, Little, RF, Kahl, BS & Smith, MR 2017, 'Recommendations for clinical trial development in mantle cell lymphoma', Journal of the National Cancer Institute, vol. 109, no. 1, djw263. https://doi.org/10.1093/jnci/djw263
Spurgeon, Stephen ; Till, Brian G. ; Martin, Peter ; Goy, Andre H. ; Dreyling, Martin P. ; Gopal, Ajay K. ; LeBlanc, Michael ; Leonard, John P. ; Friedberg, Jonathan W. ; Baizer, Lawrence ; Little, Richard F. ; Kahl, Brad S. ; Smith, Mitchell R. / Recommendations for clinical trial development in mantle cell lymphoma. In: Journal of the National Cancer Institute. 2017 ; Vol. 109, No. 1.
@article{2449d5fabe6a48e7802d06d48d2df0e6,
title = "Recommendations for clinical trial development in mantle cell lymphoma",
abstract = "Mantle cell lymphoma (MCL) comprises around 6{\%} of all non-Hodgkin's lymphoma (NHL) diagnoses. In younger patients, age less than 60 to 65 years, aggressive induction often followed by consolidation with autologous stem cell transplant has suggested improved outcomes in this population. Less intensive therapies in older patients often followed by maintenance have been studied or are under active investigation. However, despite recent advances, MCL remains incurable, with a median overall survival of around five years. Patients with high-risk disease have particularly poor outcomes. Treatment varies widely across institutions, and to date no randomized trials comparing intensive vs less intensive approaches have been reported. Although recent data have highlighted the heterogeneity of MCL outcomes, patient assessment for treatment selection has largely been driven by patient age with little regard to fitness, disease biology, or disease risk. One critical advance is the finding that minimal residual disease status (MRD) after induction correlates with long-term outcomes. As such, its use as a potential end point could inform clinical trial design. In order to more rapidly improve the outcomes of MCL patients, clinical trials are needed that prospectively stratify patients on the basis of MCL biology and disease risk, incorporate novel agents, and use MRD to guide the need for additional therapy.",
author = "Stephen Spurgeon and Till, {Brian G.} and Peter Martin and Goy, {Andre H.} and Dreyling, {Martin P.} and Gopal, {Ajay K.} and Michael LeBlanc and Leonard, {John P.} and Friedberg, {Jonathan W.} and Lawrence Baizer and Little, {Richard F.} and Kahl, {Brad S.} and Smith, {Mitchell R.}",
year = "2017",
doi = "10.1093/jnci/djw263",
language = "English (US)",
volume = "109",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Recommendations for clinical trial development in mantle cell lymphoma

AU - Spurgeon, Stephen

AU - Till, Brian G.

AU - Martin, Peter

AU - Goy, Andre H.

AU - Dreyling, Martin P.

AU - Gopal, Ajay K.

AU - LeBlanc, Michael

AU - Leonard, John P.

AU - Friedberg, Jonathan W.

AU - Baizer, Lawrence

AU - Little, Richard F.

AU - Kahl, Brad S.

AU - Smith, Mitchell R.

PY - 2017

Y1 - 2017

N2 - Mantle cell lymphoma (MCL) comprises around 6% of all non-Hodgkin's lymphoma (NHL) diagnoses. In younger patients, age less than 60 to 65 years, aggressive induction often followed by consolidation with autologous stem cell transplant has suggested improved outcomes in this population. Less intensive therapies in older patients often followed by maintenance have been studied or are under active investigation. However, despite recent advances, MCL remains incurable, with a median overall survival of around five years. Patients with high-risk disease have particularly poor outcomes. Treatment varies widely across institutions, and to date no randomized trials comparing intensive vs less intensive approaches have been reported. Although recent data have highlighted the heterogeneity of MCL outcomes, patient assessment for treatment selection has largely been driven by patient age with little regard to fitness, disease biology, or disease risk. One critical advance is the finding that minimal residual disease status (MRD) after induction correlates with long-term outcomes. As such, its use as a potential end point could inform clinical trial design. In order to more rapidly improve the outcomes of MCL patients, clinical trials are needed that prospectively stratify patients on the basis of MCL biology and disease risk, incorporate novel agents, and use MRD to guide the need for additional therapy.

AB - Mantle cell lymphoma (MCL) comprises around 6% of all non-Hodgkin's lymphoma (NHL) diagnoses. In younger patients, age less than 60 to 65 years, aggressive induction often followed by consolidation with autologous stem cell transplant has suggested improved outcomes in this population. Less intensive therapies in older patients often followed by maintenance have been studied or are under active investigation. However, despite recent advances, MCL remains incurable, with a median overall survival of around five years. Patients with high-risk disease have particularly poor outcomes. Treatment varies widely across institutions, and to date no randomized trials comparing intensive vs less intensive approaches have been reported. Although recent data have highlighted the heterogeneity of MCL outcomes, patient assessment for treatment selection has largely been driven by patient age with little regard to fitness, disease biology, or disease risk. One critical advance is the finding that minimal residual disease status (MRD) after induction correlates with long-term outcomes. As such, its use as a potential end point could inform clinical trial design. In order to more rapidly improve the outcomes of MCL patients, clinical trials are needed that prospectively stratify patients on the basis of MCL biology and disease risk, incorporate novel agents, and use MRD to guide the need for additional therapy.

UR - http://www.scopus.com/inward/record.url?scp=85014821623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014821623&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw263

DO - 10.1093/jnci/djw263

M3 - Review article

C2 - 28040733

AN - SCOPUS:85014821623

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

M1 - djw263

ER -